SAVING’ jab for severe asthma that could prevent deadly attacks with just two doses a year could be available to patients in ...

The FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for people with severe asthma.

An asthma treatment that only requires patients to have two jabs a year to prevent life-threatening attacks will be available ...

The FDA approved depemokimab as an add-on maintenance treatment in patients aged at least 12 years with severe asthma and an ...

Diagnosing precisely what type of asthma a child has and fine-tuning the treatment for it involves an invasive procedure under general anesthesia. For children with mild asthma, it's just not worth ...

The FDA approved depemokimab (Exdensur) as the first ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotype, GSK announced.

As the prevalence of asthma continues to increase, the financial impact on the healthcare costs of the United States does as well. Managed care pharmacists are ideally situated to unite the shared ...

Coughing and wheezing can leave anyone wondering whether it is asthma or bronchitis at play. Both of these respiratory issues ...

What can you do to help your eosinophilic asthma treatments work their best? There are simple steps you can take each day to improve symptoms, quality of life, and overall health. Eosinophilic asthma ...

More must be done to ensure that asthma patients get access to cutting-edge treatments, experts have said, after research ...

This year’s top asthma and respiratory disorder story focused on the pushback from multiple advocacy groups following ...

Kamal Kumar Singhal, a 44-year-old resident of Uttamnagar, Delhi, has been living with asthma since 2018. Initially, he ...